Goldman Sachs Upgrades Jazz Pharmaceuticals’ Stock to ‘Buy’, Pre-Market Trading Increases

Trending News 🌥️

Jazz Pharmaceuticals Stock Intrinsic Value – Jazz Pharmaceuticals ($NASDAQ:JAZZ) is an Irish-based biopharmaceutical company focused on developing and commercializing life-transforming treatments for patients with serious unmet medical needs. Their portfolio of products, including Xyrem, Erwinaze, and Defitelio, are used to treat various conditions such as narcolepsy, acute lymphoblastic leukemia, and hepatic veno-occlusive disease. On Friday, Goldman Sachs upgraded their outlook on Jazz Pharmaceuticals’ stock, moving it from Neutral to Buy. This change in sentiment was driven by the company’s strong performance over the past few quarters and expectations for further growth in the future. The analysts at Goldman Sachs highlighted the company’s focus on developing treatments for rare diseases and its potential to continue to grow its product portfolio.

The upgrade by Goldman Sachs caused Jazz Pharmaceuticals’ stock to trade higher pre-market on Friday. This marks the latest positive development in a long string of good news for the company. For investors looking to capitalize on this positive news, now may be a good time to take a closer look at Jazz Pharmaceuticals. With Goldman Sachs now giving the stock a Buy rating, it could be an attractive option for those seeking long-term growth potential. As always, investors should do their own research before making any investment decisions.

Stock Price

On Monday, Jazz Pharmaceuticals‘ stock opened at $153.0 and closed at $152.6, up by 0.4% from the prior closing price of $152.0. The analysts at Goldman Sachs noted the strong fundamentals of Jazz Pharmaceuticals and the potential for growth in the future. The upgrade by Goldman Sachs has been seen as a positive indicator for Jazz Pharmaceuticals and has sparked excitement amongst investors. The company’s performance over the past year has been impressive and it has consistently delivered strong returns to shareholders. The company’s products are highly sought after, and its pipeline of new drugs is promising. Jazz Pharmaceuticals is well-positioned to capitalize on the increased demand for specialty drugs in the coming years.

The company is investing in research and development in order to produce innovative medicines that can help address unmet medical needs and improve patient outcomes. The company also has a strong balance sheet and is well-positioned to take advantage of opportunities in the market. The company’s fundamentals are solid and its pipeline of new drugs is promising. With the stock now being upgraded to a ‘buy’ rating, pre-market trading has increased significantly and investors are optimistic about the company’s future prospects. Live Quote…

About the Company

VI Analysis – Jazz Pharmaceuticals Stock Intrinsic Value

JAZZ PHARMACEUTICALS is a company whose fundamentals reflect its long-term potential. The VI app makes it easy to analyze the company’s value. The intrinsic value of JAZZ PHARMACEUTICALS is around $175.9, as calculated by VI Line. Currently, JAZZ PHARMACEUTICALS stock is traded at $152.6, making it a fair price that is undervalued by 13%. This presents an interesting opportunity for investors looking to capitalize on the company’s long-term potential. JAZZ PHARMACEUTICALS has a strong balance sheet, with solid cash reserves and low debt levels. It also has a strong financial position, with solid earnings, revenues and margins. This makes it a great candidate for long-term investment. Moreover, the company has a strong track record of success and its products are well-received in the market. JAZZ PHARMACEUTICALS also has a strong research and development pipeline and is actively pursuing new opportunities. This positions it well for the future, as new products and services could lead to further growth. Additionally, the company is involved in several strategic partnerships and collaborations with leading global healthcare companies, adding further potential for success. Overall, JAZZ PHARMACEUTICALS presents an attractive investment opportunity for those looking to capitalize on its long-term potential. With its strong fundamentals and potential for growth, it is a great choice for investors looking for a sound long-term option. More…

VI Peers

The company has a diversified portfolio of products in central nervous system, hematology/oncology, inflammation and other therapeutic areas. Jazz Pharmaceuticals‘ competitors include Nurix Therapeutics Inc, Incyte Corp, and Poxel SA.

– Nurix Therapeutics Inc ($NASDAQ:NRIX)

Nurix Therapeutics Inc. is a clinical-stage biopharmaceutical company, which focuses on harnessing the body’s own natural mechanisms to regulate protein function for the treatment of cancer and other diseases. The company’s lead product candidate is a first-in-class, orally available, small molecule inhibitor of the proteasome, which is in development for the treatment of relapsed or refractory multiple myeloma. Nurix was founded by Robert L. Gould, Ph.D. and Bruce A. Cohen, M.D. in December 2001 and is headquartered in San Francisco, CA.

– Incyte Corp ($NASDAQ:INCY)

Incyte Corp is a biopharmaceutical company that focuses on the discovery, development, and commercialization of proprietary therapeutics to treat serious unmet medical needs, primarily in oncology. The company’s market cap is 15.34B as of 2022 and its ROE is 9.54%. Incyte’s products include Jakafi, Iclusig, and Jakavi. Jakafi is used to treat myelofibrosis and polycythemia vera, two rare blood disorders. Iclusig is used to treat leukemias, including chronic myeloid leukemia andPhiladelphia chromosome-positive acute lymphoblastic leukemia. Jakavi is used to treat myelofibrosis, polycythemia vera, and essential thrombocythemia.

– Poxel SA ($LTS:0RA2)

Poxel SA is a French pharmaceutical company that focuses on the development and commercialization of drugs for the treatment of diabetes and obesity. The company has a market capitalization of 43.37 million as of 2022 and a return on equity of -705.2%. Poxel SA’s products include Imeglimin, which is in clinical development for the treatment of type 2 diabetes, and PXL065, which is in preclinical development for the treatment of obesity.

Summary

Investing in Jazz Pharmaceuticals can be a lucrative opportunity for investors. The company recently received a “Buy” rating upgrade from Goldman Sachs, which has resulted in increased pre-market trading. Jazz Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing innovative products in the areas of sleep, hematology/oncology, and urology. The company has a broad portfolio of approved products, including Xyrem®, Erwinaze®, Defitelio®, Vyxeos®, and Prialt®. Jazz Pharmaceuticals also has several promising development-stage products targeting a range of indications, such as narcolepsy, hematologic malignancies, and pain management. The company is currently in the process of expanding its commercial presence in Europe and Asia to further increase revenue growth.

This provides the company with the flexibility to pursue strategic acquisitions and partnerships that could further enhance its product portfolio and pipeline. The stock price of Jazz Pharmaceuticals has been steadily increasing over the last few months, and the recent upgrade from Goldman Sachs has added further momentum. Investors who are looking for exposure to the biopharmaceutical sector should consider investing in Jazz Pharmaceuticals as a long-term investment opportunity. The company’s robust pipeline, strong balance sheet, and commercial expansion plans offer a compelling opportunity for investors.